FDA Patent Clock Starts Ticking for ELAHERE's Review Period
Published Date: 5/19/2025
Notice
Summary
The FDA has officially set the review period for ELAHERE, a human biological product, which helps decide if its patent can be extended. This affects the company behind ELAHERE and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the applicant’s effort during review, you’ve got until mid-2025 to speak up—so don’t miss your chance!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Regulatory review period set at 3,867 days
FDA determined the regulatory review period for ELAHERE is 3,867 days in total: 3,635 days for the testing phase and 232 days for the approval phase. FDA verified the key dates used: IND effective April 15, 2012; BLA initially submitted March 28, 2022; BLA approved November 14, 2022.
Applicant's requested patent extension lengths
ImmunoGen, Inc. submitted patent term restoration applications for ELAHERE and in those applications seeks patent term extensions of 1,149 days; 1,677 days; 1,733 days; 1,740 days; or 1,775 days. FDA notes that the USPTO will apply statutory limitations when calculating the actual extension.
ELAHere approved under accelerated approval
FDA approved ELAHERE (mirvetuximab soravtansine-gynx) for adult patients with folate receptor alpha (FRα)–positive, platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. The approval (granted November 14, 2022) is under accelerated approval based on tumor response rate and durability of response, and continued approval may depend on a confirmatory trial.
Opportunity to challenge dates and due diligence
Anyone who believes the published dates are incorrect may submit comments and ask for a redetermination by July 18, 2025, and any interested person may petition FDA about whether the applicant acted with due diligence by November 17, 2025. The notice specifies how to submit comments and petitions electronically or by mail.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08852, Self-Regulatory Organizations; NYSE Texas, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Adopt Rule 7.35 and Amend Rule 7.31
NYSE Texas is rolling out a new Rule 7.35 to make auctions smoother and updating Rule 7.31 to add cool new order types like Imbalance Offset Orders and Q Orders. These changes affect traders and market makers by improving how trades happen, especially for certain Exchange Traded Products. The new rules kicked in right away on May 9, 2025, aiming to boost trading efficiency without extra costs.
Next: 2025-08856, Colorado River Basin Salinity Control Advisory Council Notice of Public Meeting
The Colorado River Basin Salinity Control Advisory Council is holding a public meeting on June 3, 2025, to share updates and plan future efforts to keep the river’s water clean and less salty. This affects communities and farmers relying on the river, with federal agencies reporting progress and discussing new projects. You can join in person in Utah or online by signing up before May 27.